FILTER

LATEST INTERVIEWS

Mining
Chile

Darrell White

EXECUTIVE GENERAL MANAGER AMERICAS, THIESS
Chile Mining 2021
Thiess is upbeat on adding more services and expanding its operations in Chile.
Mining
Chile

Marco Riveros

VICE PRESIDENT, CHILEAN COPPER COMMISSION (COCHILCO)
Chile Mining 2021
The Chilean Copper Commission (Cochilco) speaks to GBR about how it assisted Chile’s copper industry through a difficult period.
Italy
Pharma & Life Sciences

Giovanni Sala

GENERAL MANAGER, MEDAC PHARMA
Medac Pharma explains how producers of original drugs struggle to gain a fair price in Italy.
Italy
Pharma & Life Sciences

Enrique Hausermann

PRESIDENT, EGUALIA
Egualia is the Italian association for generics, biosimilars and VMAs and comments on some of the challenges that its’ members face.
Mining
South Africa
MACIG

Roger Baxter

CEO, MINERALS COUNCIL SOUTH AFRICA
The Minerals Council of South Africa explains how it is working with the government to revive the country’s mining sector.
United States
Pharma & Life Sciences

Michael Quirmbach

CEO & PRESIDENT, CORDENPHARMA
CordenPharma is enjoying great demand for its increasing array of services.
Petrochemicals & Chemicals
Singapore

Mark Tonner & Michael Lambert

CEO, NAUTICOL ENERGY (CANADA) & CFO, FORTREC (SINGAPORE)
Singapore Chemicals 2021
Introducing the World Scale - Net Zero Canadian methanol project.
United States
Pharma & Life Sciences

Alan Petro

CEO, NEW VISION PHARMACEUTICALS
New Vision Pharmaceuticals explains how it is developing Blow-Fill-Seal technology and other services.
Mining
Canada

Jon Deluce

CEO, MELKIOR RESOURCES
Melkior Resources describes its strategy for developing its assets in Ontario and Québec.
Italy
Pharma & Life Sciences

Luca Candioli

OWNER & GENERAL MANAGER, CANDIOLI PHARMA
Italian animal health company Candioli explains how it intends to double in size during the next five years.

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
MORE PREVIOUSLY PUBLISHED

PARTNER EVENTS

SEE ALL